[go: up one dir, main page]

IL318656A - Sars-cov2 main protease inhibitors - Google Patents

Sars-cov2 main protease inhibitors

Info

Publication number
IL318656A
IL318656A IL318656A IL31865625A IL318656A IL 318656 A IL318656 A IL 318656A IL 318656 A IL318656 A IL 318656A IL 31865625 A IL31865625 A IL 31865625A IL 318656 A IL318656 A IL 318656A
Authority
IL
Israel
Prior art keywords
cov2
sars
protease inhibitors
main protease
main
Prior art date
Application number
IL318656A
Other languages
Hebrew (he)
Inventor
Stephen E Ammann
Xinpei Cai
Eda Y Canales
Weng K Chang
Gregory F Chin
Henok H Kinfe
Scott E Lazerwith
Jessica L Mckinley
Michael R Mish
Devan Naduthambi
Jason K Perry
Kevin X Rodriguez
Scott D Schroeder
Christopher J Swank
Veldhuizen Joshua J Van
Original Assignee
Gilead Sciences Inc
Stephen E Ammann
Xinpei Cai
Eda Y Canales
Weng K Chang
Gregory F Chin
Henok H Kinfe
Scott E Lazerwith
Jessica L Mckinley
Michael R Mish
Devan Naduthambi
Jason K Perry
Kevin X Rodriguez
Scott D Schroeder
Christopher J Swank
Veldhuizen Joshua J Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Stephen E Ammann, Xinpei Cai, Eda Y Canales, Weng K Chang, Gregory F Chin, Henok H Kinfe, Scott E Lazerwith, Jessica L Mckinley, Michael R Mish, Devan Naduthambi, Jason K Perry, Kevin X Rodriguez, Scott D Schroeder, Christopher J Swank, Veldhuizen Joshua J Van filed Critical Gilead Sciences Inc
Publication of IL318656A publication Critical patent/IL318656A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL318656A 2022-08-05 2023-08-04 Sars-cov2 main protease inhibitors IL318656A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263370629P 2022-08-05 2022-08-05
US202263375522P 2022-09-13 2022-09-13
US202263476359P 2022-12-20 2022-12-20
US202363482750P 2023-02-01 2023-02-01
US202363486156P 2023-02-21 2023-02-21
US202363508350P 2023-06-15 2023-06-15
PCT/US2023/071744 WO2024031089A1 (en) 2022-08-05 2023-08-04 Sars-cov2 main protease inhibitors

Publications (1)

Publication Number Publication Date
IL318656A true IL318656A (en) 2025-03-01

Family

ID=87889341

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318656A IL318656A (en) 2022-08-05 2023-08-04 Sars-cov2 main protease inhibitors

Country Status (6)

Country Link
US (3) US20240239807A1 (en)
AU (1) AU2023320566A1 (en)
CO (1) CO2025001287A2 (en)
IL (1) IL318656A (en)
TW (1) TW202408511A (en)
WO (1) WO2024031089A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds
TW202408511A (en) * 2022-08-05 2024-03-01 美商基利科學股份有限公司 Sars-cov2 main protease inhibitors

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284661A (en) 1990-02-22 1994-02-08 Takeda Chemical Industries, Ltd. Fused thiophene derivatives, their production and use
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
ES2389063T3 (en) 2007-05-04 2012-10-22 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
EA033598B1 (en) 2011-11-11 2019-11-07 Gilead Apollo Llc Acc inhibitors and uses thereof
AR106472A1 (en) 2015-10-26 2018-01-17 Gilead Apollo Llc ACC INHIBITORS AND USES OF THE SAME
RU2019136536A (en) 2017-05-16 2021-06-16 Аннцзи Фармасьютикал Ко., Лтд. HISTONE DEACETYLASE INHIBITORS (HDAC)
EP3875078A1 (en) * 2020-03-06 2021-09-08 Dompe' Farmaceutici S.P.A. Compounds for the treatment of covid-19
CN111440188B (en) 2020-04-10 2022-03-08 江苏海悦康医药科技有限公司 Preparation method of Relugol (Relugolix) key intermediate
CN112778310A (en) 2020-04-20 2021-05-11 中国科学院上海药物研究所 Application of nucleoside analogue or combination preparation containing nucleoside analogue in resisting virus
WO2021228762A1 (en) * 2020-05-11 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tmprss2 inhibitors for the treatment of lung viral infections
CN111793078B (en) 2020-07-03 2022-02-01 东莞市东阳光新药研发有限公司 Bicyclic nitrogen-containing heteroaryl substituted pyrimidinediones and application thereof
CN111875614B (en) 2020-07-03 2022-04-29 东莞市东阳光新药研发有限公司 Heterocyclyl-substituted thieno [2,3-d ] pyrimidine-2, 4(1H,3H) -diones and their use
CN111909168B (en) 2020-07-31 2022-02-01 广东东阳光药业有限公司 Nitrogenous heterocyclic group substituted pyrimidinediones and uses thereof
CN111925379B (en) 2020-07-31 2022-02-15 广东东阳光药业有限公司 Nitrogen-containing heteroaryl substituted pyrimidinediones and uses thereof
FI4204421T3 (en) 2020-08-27 2024-06-25 Gilead Sciences Inc Compounds and methods for treatment of viral infections
CN113754679B (en) 2020-09-09 2023-04-07 广东东阳光药业有限公司 Substituted pyrimidinediones and their use
CN112047957B (en) 2020-09-09 2022-02-01 广东东阳光药业有限公司 Substituted pyrimidinediones and their use
CN112142757B (en) 2020-09-29 2022-02-15 广东东阳光药业有限公司 Five-membered nitrogen-containing heteroaryl substituted pyrimidinedione compound and application thereof
WO2022067573A1 (en) 2020-09-29 2022-04-07 广东东阳光药业有限公司 Sulfonamide-substituted heteroaryl pyrimidinedione compound and use thereof
WO2022067566A1 (en) 2020-09-29 2022-04-07 广东东阳光药业有限公司 Pyrimidinedione compound containing saturated oxygen-containing heterocyclic group and use thereof
EP4267582A4 (en) 2020-12-30 2024-06-05 Southern University of Science and Technology METHODS AND MODIFIED NUCLEOSIDES FOR THE TREATMENT OF CORONAVIRUS INFECTIONS
WO2022150962A1 (en) 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
WO2022224223A1 (en) 2021-04-23 2022-10-27 Novartis Ag Compounds and compositions for the treatment of coronaviral related diseases
MA53521B1 (en) 2021-05-12 2023-03-31 Univ Ibn Tofail New mpro protease and sars-cov2 replication inhibitor compounds, their formulations and applications
WO2022251647A1 (en) 2021-05-28 2022-12-01 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibitors of sars-cov-2 viral replication and uses thereof
US20240293380A1 (en) 2021-06-16 2024-09-05 The Cleveland Clinic Foundation Protease inhibitors and methods of use
WO2023283831A1 (en) 2021-07-14 2023-01-19 上海药明康德新药开发有限公司 Virus main protease inhibitor, preparation method therefor, and use
EP4373487A1 (en) 2021-07-19 2024-05-29 Baylor College of Medicine Coronavirus main protease inhibitors and methods using same
TW202321210A (en) 2021-07-22 2023-06-01 瑞士商諾華公司 Compounds and compositions for the treatment of coronaviral related diseases
EP4396175A1 (en) 2021-08-31 2024-07-10 Pardes Biosciences, Inc. Crystalline inhibitors of cysteine proteases and methods of use thereof
CN115745960B (en) 2021-09-02 2024-08-30 中国科学院上海药物研究所 A class of compounds containing quinolinone amide and preparation method, pharmaceutical composition and use thereof
JP2024178473A (en) 2021-09-03 2024-12-25 塩野義製薬株式会社 Bicyclic nitrogen-containing heterocyclic derivatives having virus proliferation inhibitory activity and pharmaceutical compositions containing the same
US20250042889A1 (en) 2021-09-07 2025-02-06 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. 3clpro protease inhibitor
WO2023042879A1 (en) * 2021-09-17 2023-03-23 塩野義製薬株式会社 Bicyclic heterocyclic derivative having viral growth inhibitory activity and pharmaceutical composition containing same
US12186309B2 (en) 2021-09-27 2025-01-07 The Governors Of The University Of Alberta RNA virus inhibitor compounds and uses thereof
TW202330513A (en) 2021-09-28 2023-08-01 加拿大商愛彼特生物製藥公司 ) inhibitors and methods using same
WO2023054292A1 (en) 2021-09-28 2023-04-06 塩野義製薬株式会社 Pharmaceutical composition containing triazine derivative
WO2023054759A1 (en) 2021-09-30 2023-04-06 한국화학연구원 2-aminoquinazoline derivative and anti-viral composition comprising same
CN116003495A (en) 2021-10-22 2023-04-25 广州谷森制药有限公司 Novel deuterated purine nucleoside compound, preparation method, composition and application thereof
CN116003509A (en) 2021-10-22 2023-04-25 广州谷森制药有限公司 Novel deuterated benzothiazole compound, preparation method, composition and application thereof
CN114957381A (en) 2021-10-22 2022-08-30 广州谷森制药有限公司 Novel deuterated cyano compound, preparation method, composition and application thereof
EP4289432A4 (en) 2021-11-24 2025-01-15 Shionogi & Co PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES
WO2023095860A1 (en) 2021-11-26 2023-06-01 塩野義製薬株式会社 Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug
CN114031626A (en) 2021-12-09 2022-02-11 成都科圣原医药科技有限公司 Synthetic method of Ruogeli
EP4448105A1 (en) 2021-12-16 2024-10-23 VIR Biotechnology, Inc. Heterocycle derivatives for the treatment of disease
CN116265440B (en) 2021-12-16 2024-09-27 贵州大学 A salicylic acid spliced pyridone compound and its preparation method and application
WO2023122260A2 (en) 2021-12-22 2023-06-29 The Texas A&M University System Inhibitors of sars-cov-2
US20250099474A1 (en) 2022-01-19 2025-03-27 Shionogi & Co., Ltd. Pharmaceutical for treatment of novel coronavirus infection
CN116514795A (en) 2022-01-29 2023-08-01 齐鲁制药有限公司 Process for preparing 3CLpro protease inhibitors
CN116655606A (en) 2022-02-18 2023-08-29 广州谷森制药有限公司 Novel deuterated triazine compound, its preparation method, composition and application
WO2023155830A1 (en) 2022-02-18 2023-08-24 南京明德新药研发有限公司 Pyridone or pyrimidone derivative and application thereof
US20230263771A1 (en) 2022-02-21 2023-08-24 University Of Houston System Small molecules that treat or prevent viral infections
WO2023165459A1 (en) 2022-03-01 2023-09-07 Fochon Biosciences , Ltd. Compounds as sars-cov-2 inhibitors
AU2023231321A1 (en) 2022-03-10 2024-10-31 Jkt Biopharma Co., Ltd. Triazine compound, intermediate thereof, preparation method therefor and use thereof
CN114539228A (en) 2022-03-14 2022-05-27 药康众拓(江苏)医药科技有限公司 Triazine compound or pharmaceutically acceptable salt, isomer, pharmaceutical composition and application thereof
CN116284133B (en) 2022-03-24 2024-03-29 南京知和医药科技有限公司 Novel six-membered heterocyclic derivative, and pharmaceutical composition and application thereof
CN116891484A (en) 2022-03-31 2023-10-17 江苏恒瑞医药股份有限公司 Fused ring compounds, their preparation methods and their applications in medicine
CN116514784A (en) 2022-04-01 2023-08-01 深圳安泰维生物医药有限公司 A kind of triazine compound and its application
WO2023195530A1 (en) 2022-04-08 2023-10-12 塩野義製薬株式会社 Uracil derivative having viral growth inhibitory activity and pharmaceutical composition containing same
WO2023208200A1 (en) 2022-04-29 2023-11-02 北京凯因科技股份有限公司 3cl protease inhibitor
CN117069705A (en) 2022-05-09 2023-11-17 嘉兴安谛康生物科技有限公司 1,3, 5-triazine-2, 4-dione derivatives for use in anti-novel coronavirus therapy
CN116768867A (en) 2022-05-19 2023-09-19 深圳安泰维生物医药有限公司 Triazine derivative compound and application thereof
CN117088869A (en) 2022-05-20 2023-11-21 上海翊石医药科技有限公司 3CL protease inhibitor and preparation method and application thereof
CN117126141A (en) 2022-05-25 2023-11-28 成都施贝康生物医药科技有限公司 Dihydropyrimidine compounds, preparation and application thereof
WO2023227117A1 (en) 2022-05-27 2023-11-30 广州国家实验室 3c-like protease inhibitor
CN119255987A (en) 2022-05-27 2025-01-03 广州国家实验室 3C-like protease inhibitor
WO2023226679A1 (en) 2022-05-27 2023-11-30 广州国家实验室 3c-like protease inhibitor
KR102731073B1 (en) 2022-06-21 2024-11-15 한국화학연구원 Quinolone derivatives, pharmaceutically acceptable salt thereof, and antibiral composition containing the same as an active ingredient
WO2024010585A1 (en) 2022-07-07 2024-01-11 Yale University Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use
WO2024008909A1 (en) 2022-07-08 2024-01-11 Janssen Pharmaceutica Nv Inhibitors of coronavirus
CN116496266A (en) 2022-07-08 2023-07-28 歌礼生物科技（杭州）有限公司 Triazine derivatives
WO2024009120A1 (en) 2022-07-08 2024-01-11 Ascletis Bioscience Co., Ltd. Triazine derivatives and methods of use thereof
CN117402185A (en) 2022-07-14 2024-01-16 广东东阳光药业股份有限公司 Triazine compound and application thereof in medicines
WO2024017178A1 (en) 2022-07-18 2024-01-25 Avitar Biosciences, Inc. Substituted hydantoin compounds, pharmaceutical compositions, and therapeutic applications
CN117430590A (en) 2022-07-20 2024-01-23 江苏恒瑞医药股份有限公司 Cyclopropyl compound, preparation method thereof and application thereof in medicine
CN117466873A (en) 2022-07-29 2024-01-30 广东东阳光药业股份有限公司 Pyrimidine compound and application thereof in medicines
TW202408511A (en) * 2022-08-05 2024-03-01 美商基利科學股份有限公司 Sars-cov2 main protease inhibitors
CN115894504A (en) 2022-10-21 2023-04-04 深圳信立泰药业股份有限公司 Coronavirus 3CL protease inhibitor and application thereof
CN115894443B (en) 2022-11-17 2024-03-29 上海市重大传染病和生物安全研究院 Compound Ai Kuisi and application thereof
CN116514783A (en) 2022-11-21 2023-08-01 歌礼生物科技（杭州）有限公司 Triazine derivatives
CN116041349B (en) 2022-12-27 2023-10-20 吉斯凯(苏州)制药有限公司 Xanthine compound, preparation method thereof and application thereof in preparation of novel coronavirus 3CL protease inhibitor
CN116554153A (en) 2023-04-24 2023-08-08 中国人民解放军军事科学院军事医学研究院 Tertiary amide compounds and their medicinal uses
CN116621817B (en) 2023-07-20 2023-09-29 爱斯特（成都）生物制药股份有限公司 Entecavir fumarate crystal form, preparation method, pharmaceutical composition and application thereof

Also Published As

Publication number Publication date
WO2024031089A1 (en) 2024-02-08
US20240239807A1 (en) 2024-07-18
AU2023320566A1 (en) 2025-02-20
US12091420B2 (en) 2024-09-17
TW202408511A (en) 2024-03-01
US20250042915A1 (en) 2025-02-06
CO2025001287A2 (en) 2025-02-24
US20240116946A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
IL308694A (en) Protease inhibitors as antivirals
IL318656A (en) Sars-cov2 main protease inhibitors
IL307188A (en) Nlrp3 inhibitors
IL289914A (en) Enzyme inhibitors
IL289863A (en) Enzyme inhibitors
IL289778A (en) Enzyme inhibitors
IL289764A (en) Plasma kallikrein inhibitors
IL289783A (en) Enzyme inhibitors
IL314049A (en) Parp7 inhibitors
IL289214A (en) Crystalline forms of plasma kallikrein inhibitors
IL309182A (en) Protease inhibitors for the treatment of coronavirus infections
EP4164634A4 (en) Plasma kallikrein inhibitors
IL314800A (en) Irak4 inhibitors
GB202308197D0 (en) Protease
GB202216121D0 (en) Peptide inhibitor
GB202301059D0 (en) PHD inhibitors
GB202301050D0 (en) PHD Inhibitors
GB202309514D0 (en) Enzyme inhibitors
GB202215462D0 (en) Enzyme inhibitors
GB202212081D0 (en) Enzyme inhibitors
GB202106284D0 (en) Enzyme inhibitors
GB202104788D0 (en) Enzyme inhibitors
GB202102384D0 (en) Enzyme inhibitors
GB202018970D0 (en) Enzyme inhibitors
GB202004636D0 (en) Enzyme inhibitor